Skip to main content


Fig. 2 | Journal of Patient-Reported Outcomes

Fig. 2

From: Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)

Fig. 2

Observed scores by arm over time for the BPI Pain Interference and SF-36 Energy/Vitality scales. Arm and assessment specific sample sizes are shown in the bars. Ninety-five percent confidence intervals for the observed rates are indicated by the vertical lines at the tops of the bars

Back to article page